Green Journals

Year	A	B
2026	✓	✓
2025	✓	✓
2024	✓	✓
2023	✓	✓
2021/2022	✓	✓
2020	✓	✓
2019
2018

Prevalence, risk factors, and racial disparities in probable and possible dementia: the national health and aging trends study

Young-Shin Lee, Juan A. Cruz, Michelle Kabakibi et al.

2026-12 Vol. 13 Issue 10 Pages 100676

DOI: 10.1016/j.tjpad.2026.100676

Autopsy findings in Alzheimer's disease clinical trial participants demonstrate a high frequency of off-target coexisting pathologic features

E. Pinar Coskun, Justin Barber, Lauren Bojarski et al.

2026-12 Vol. 13 Issue 10 Pages 100669

DOI: 10.1016/j.tjpad.2026.100669

Feasibility of immersive 40 Hz gamma sensory stimulation in early-stage Alzheimer’s disease

Carolina Reis, Laura Hainke, Gabriel Headley et al.

2026-12 Vol. 13 Issue 10 Pages 100679

DOI: 10.1016/j.tjpad.2026.100679

Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France

Lisa Le Scouarnec, Vincent Bouteloup, Leslie Grasset et al.

2026-12 Vol. 13 Issue 10 Pages 100683

DOI: 10.1016/j.tjpad.2026.100683

Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center

Yuki Kujuro, Marina Saito, Manami Maruko et al.

2026-12 Vol. 13 Issue 10 Pages 100686

DOI: 10.1016/j.tjpad.2026.100686

Cerebral microhemorrhage and cognition in preclinical Alzheimer’s disease

Dobri Baldaranov, Shunran Wang, Rema Raman et al.

2026-12 Vol. 13 Issue 10 Pages 100681

DOI: 10.1016/j.tjpad.2026.100681

Characterization of a metabolomics signature of the brain-health-promoting MIND diet in older persons

Jeanne Neuffer, Raúl González-Domínguez, Sophie Lefèvre-Arbogast et al.

2026-12 Vol. 13 Issue 10 Pages 100670

DOI: 10.1016/j.tjpad.2026.100670

Pharmacological interventions for reducing the risk of cognitive decline and dementia after stroke/transient ischemic attack: A systematic review

Colin Rosenau, Lieke Bakker, Veerle van Gils et al.

2026-12 Vol. 13 Issue 10 Pages 100680

DOI: 10.1016/j.tjpad.2026.100680

Evoke (+) trials of semaglutide for early alzheimer’s disease: Innovations, lessons, and implications

Jeffrey L. Cummings, Philip Scheltens

2026-12 Vol. 13 Issue 10 Pages 100677

DOI: 10.1016/j.tjpad.2026.100677

Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease

Alberto Benussi, Federica Agosta, Luisa Agnello et al.

2026-12 Vol. 13 Issue 10 Pages 100685

DOI: 10.1016/j.tjpad.2026.100685

Journal Report

Journal Information

Classification History

Recent Articles